Review Mortgage Lenders

Acura Mortgage

Camaro puts aggressive Acura back in its place

100% stock (right down to the paper air filter) 1993 LT1 powered Camaro automatic, out for a cruise after a couple base Dyno pulls, and ran into ...

Police Blotter | Islander reports purse stolen during church service

Crime statistics for May

Every month, the Police Department calculates crime statistics and compares them to numbers from the year prior.

In May of this year, there were 92 serious offenses, compared to 54 in 2014.

The largest increase was in the theft category, from 27 in 2014 to 69 in 2015.

But the department had no cases of robbery or assault, and one fewer incident of both burglary and identity theft.

This year, there were 12 adult arrests and three juvenile arrests. Police arrested 24 adults and one juvenile last May.

There were 1,779 calls for service in May this year, compared to 2,003 in 2014.


May 22

Found property: A 25-year-old Seattle man found a pile of mail and two credit cards in the street at the 4100 block of 93rd Avenue S.E.

Investment Analysts' Ratings Reiterations for June, 17th (AAVL, ACUR, DHX ...

Had its buy rating reissued by analysts at MLV & Co.. They currently have a $2.00 price target on the stock. The analysts wrote, “Acura Pharmaceuticals Inc. stock (ACUR) before today’s news has outperformed the Nasdaq Biotechnology Index YTD (up 84% vs. 20%, respectively), as in our view, investors recognize Acura’s operational progress in 2015. We would continue to be buyers of the stock at current prices, as we believe the company’s clinical and partnership strategy, which is clearly in line with newly-codified FDA guidance for development of abuse-deterrent opioid drugs, is paying dividends. As an example, we point to the announcement today of an exclusive worldwide license to Bayer Healthcare LLC for use Acura’s IMPEDE technology to develop a methamphetamine-resistant pseudoephedrine-containing product. We also point to Acura’s recent announcement to advance additional formulations of opioid products with Limitx, its next-generation, abuse-deterrent technology. We believe Acura poised to further monetize its technologies and advance multiple products that have near-term potential for value creation.””